Ta yaya CBL‑514 ke aiki? Ilimin kimiyya
Da'awar da ake yi game da CBL‑514 ba ita ce “yana narkewa” kitse ba. Da'awar ita ce tana tilastawa ƙwayoyin kitse su shiga mutuwar ƙwaya (apoptosis) a wuri da aka saka maganin. Wannan bambanci ne ke ƙayyade duk abin da ake tsammani za a gani, abin da masu bincike suka auna, da abin da hujja ke nuna (ko ba ta nuna ba).
Lura kan suna: Sinadarin CBL‑514, ba “CL‑514” ba. Wannan shi ne ƙwanƙwasa ƙwayar da kamfanin Caliway Biopharmaceuticals (New Taipei City, Taiwan) ke gwadawa. Ba ƙaraɗi ba ne, ba maganin shan ruwa ba, kuma ba samfurin da aka amince da shi ga jama'a ba. A cikin gwajin da ake magana a kai an bayar da shi a matsayin allurar subcutaneous a cikin ƙashin kitse.
Da'awar kwayoyin: DYRK1b, caspase‑3, da Bax/Bcl‑2
Takardar Phase 2 ta 2025 ta bayyana CBL‑514 a matsayin "ƙananan allurar da ke haifar da lipolysis kuma ke ƙarfafa apoptosis na adipocyte don rage kitse a ƙasa da fata a gwaje‑gwajen marasa cuta." Hanyar aiki da aka fi bayani ta fito ne daga takardar Phase 2a (Goodman et al., 2022) wadda ta ce gwaje‑gwajen marasa cuta sun nuna CBL‑514:
- yana hanawa DYRK1b, wani kinase da ke kula da tsawon rayuwar sel;
- yana ƙara yawan caspase‑3 da Bax/Bcl‑2, waɗanda ke jagorantar apoptosis;
- yana haifar da apoptosis na adipocyte, a in‑vitro da in‑vivo.
Takardar Phase 2a ta kuma ba da rahoton lipolysis a in‑vitro da rage kitse a ƙasa da fata a gwaje‑gwajen dabbobi.
A takaice, da'awar ita ce maganin na katsalandan da siginar tsira a ƙwayoyin kitse kuma yana tilastawa sel ɗin shiga cikin hanyar mutuwarsu. Caspase‑3 shi ne enzyme mafi muhimmanci wajen kaddamar da apoptosis. Daidaiton Bax/Bcl‑2 kuma alama ce da ake amfani da ita don tantance ko sel na karkata ga mutuwa ko tsira.
Abubuwan da ba mu sani ba
Akwai manyan ƙuntatawa. Sakamakon da aka ambata su ne a rahotannin sirri da ba a wallafa ba daga Caliway, don haka kamfanin ne ya bayar da su ba tare da cikakken bayani a cikin takardar Phase 2 ba. Haka kuma, takardun da aka buga ba su bayyana tsarin sinadarin CBL‑514 ba. Ba tare da wannan bayani ba, ba wanda zai iya tantance menene ainihin sinadirin, yadda yake ɗaure DYRK1b, ko kuma ko inhibtion na DYRK1b ke da cikakkiyar hujja ba.
Mutuwar ƙwayar kitse a wuri ɗaya, ba ƙara metabolism ba
Mekanik da ake ba da shi ba yana da alaka da ƙara saurin metabolism ko ƙara yawan kuzari gaba ɗaya. Manufar ita ce a wuri: a saka maganin a cikin kitse na ƙasa da fata, a haifar da apoptosis a wannan wuri, sannan a auna raguwar kauri da girman kitse ta hanyar ultrasound.
Bayanan nauyin jiki daga gwajin Phase 2 sun dace da wannan tunani. Canjin nauyin ba ya bayyana sosai: +0.45 kg a makon 4 da +0.02 kg a makon 8 a ƙungiyar CBL‑514, yayin da placebo ya rage –0.76 kg da –0.26 kg. Masu rubutu sun ce ba su ga canjin nauyi ko BMI mai ma’ana ba, kuma sun lura da raguwar kitse a wuri ɗaya har a wasu mahalarta da suka ƙara fiye da 1 kg (ba a bayyana cikakken bayanin ba). Wannan shi ne raguwar girman kitse a wuri, ba raguwar ƙarfi ba.
Abin da gwajin ɗan adam ya auna
Binciken Phase 2 (Gold et al., Aesthetic Surgery Journal, 2025) an tsara shi a matsayin randomized, single‑blind, placebo‑controlled a cibiyoyi biyar a Amurka da Australia. Mahalarta sun karɓi allura har zuwa huɗu a tazara na makonni 4. Kowace allura ta ba da 2.4 mL na CBL‑514 a 2 mg/cm², har zuwa 600 mg a kowanne magani, ko ruwa mai gishiri a matsayin placebo. Girman kitse an ƙididdige shi daga kaurin ultrasound a maki huɗu da aka ninka da yanki na cm² 300.
Masu rubutu sun ba da rahoton cewa gwajin ya cika babban manufa. A cikin nazarin intention‑to‑treat, 63.9 % na mahalarta CBL‑514 (23/36) sun sami ragin girman kitse na aƙalla 150 mL a makon 4, yayin da 17.4 % (4/23) na placebo suka cimma haka. A makon 8 adadin su ne 69.6 % (16/23) vs 0 % (0/16). Canjin matsakaicin least‑squares daga asali a ƙungiyar CBL‑514 ya kasance ‑199.80 mL a makon 4 da ‑209.46 mL a makon 8.
Wadannan sakamako ba su da alaƙa da hujjar mekanik. Gwajin ya auna girma, kauri, hotuna, da aminci. Bai ba da biopsi na ɗan adam ko bayanan caspase ba, don haka babu wani abu a cikin takardar da ke nuna cewa an sami inhibtion na DYRK1b ko apoptosis na adipocyte a mutanen da aka yi wa magani. Bayanan ɗan adam kawai sun nuna raguwar kaurin kitse da ultrasound ke auna. Bayanin apoptosis ya kasance har yanzu tunani da aka ɗauka daga gwaje‑gwajen marasa cuta.
Karanta sakamakon da hankali
Wasu ƙuntatawa na da muhimmanci ga duk mai nazari:
- Single‑blind kawai – Mahalarta sun kasance blinded, amma masu bincike, ma’aikatan wurin, da masu tallafa ba su kasance ba.
- Yawan mutuwar mahalarta – Daga mahalarta 75 da aka yi wa magani, 37 (49.3 %) ba su kammala gwajin ba. Adadin wadanda suka fice ya ragu a kowanne mataki, kuma yawan mahalarta da suka bi protocol ya rage zuwa mutane 30 kacal.
- Shiga kamfanin – Caliway ta halarci tsara gwaji, tattara bayanai, nazari, fassara, da yanke shawarar gabatarwa.
- Samfurin gwaji na bincike – Ba a yi gyara ba don yawan gwaje‑gwaje.
- Mahalarta mafi yawansu mata ne (94 % a ƙungiyar CBL‑514).
Masu rubutun sun ce sakamakon "ya yi daidai da na liposuction" kuma "yana bayyana fiye da wasu gwaje‑gwajen cryolipolysis". Waɗannan fassarori ne na masu rubutu; hanyoyin auna sun bambanta, kuma ba a yi kwatancen kai tsaye ba.
Yadda wannan ya bambanta da ATX‑101
Maganin da FDA ta amince da shi don rage kitse shi ne ATX‑101 (deoxycholic acid, Kybella), wanda aka amince da shi ne kawai don kitse a ƙasan goshi (submental). ATX‑101 yana aiki ta hanyar adipocytolysis – wani yanayi daban da apoptosis da aka ƙayyade don CBL‑514 – kuma takardun suna nuna damuwa game da yuwuwar rauni ga ƙwayoyin da ba a nufi ba.
CBL‑514 an bayyana shi a matsayin maganin da ke ƙarfafa rage kitse ba tare da necrosis na fata, ulceration, ko rauni na ƙashi ba a gwaje‑gwajen marasa cuta. Masu rubutu na Phase 2 sun ba da rahoton babu irin waɗannan abubuwa a gwajinsu.
Wannan yana nuna cewa sakamakon na daga matakin tsakiyar bincike ne, ba hujja ba don amincin dogon lokaci. Gwajin ya yi ƙanƙanta, ya samu yawan mutuwar mahalarta, kuma ba a tsara shi don magance tambayoyin aminci na tsawon lokaci ba.
Karshe
Mekanik da aka ƙayyade na CBL‑514 shi ne: hanawa DYRK1b, ƙara yawan caspase‑3 da Bax/Bcl‑2, da haifar da apoptosis na adipocyte a wuri da aka yi magani. Bayanan ɗan adam sun nuna raguwar kitse da aka auna ta ultrasound a kan placebo. Hanyar da ke haɗa waɗannan biyun ba a nuna a cikin mutane ba, kuma hujjar kwayoyin na fitowa ne daga rahotannin kamfani da ba a wallafa ba. CBL‑514 har yanzu yana cikin gwaji, kuma wannan labarin ba jagora bane don amfani.
Hanyoyin da aka ambata
- Phase 2: Gold M, et al. Aesthetic Surgery Journal. 2025;45(6):611‑620. Full text (PMC12080885) | PubMed | DOI
- Earlier Phase 2a (open‑label): Goodman GJ, et al. Aesthetic Surgery Journal. 2022;42:NP662‑NP674. PMC9384315 | DOI